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Strengths and limitations of this study
 ► This study provides a novel research approach to 
patients with multiple scleroris (MS), exploring the 
relationship between disease-specific variables, 
resilience and psychological adjustment after 
diagnosis.
 ► Study results are expected to expand the under-
standing of resilience determinants in young adults 
with MS and to inform resilience interventions with 
the potential of improving patients’ quality of life, 
well-being and adherence to MS care strategies.
 ► The present study has the advantage of recruiting 
patients with MS at a young age, early after diagno-
sis and before disease-modifying therapy initiation, 
therefore limiting the impact of long-standing dis-
ease and treatment on psychosocial characteristics.
 ► The methodological approach is multidisciplinary 
and it favours an integrated vision of MS presenta-
tion from different perspectives.
 ► Study limitations include the cross-sectional design 
preventing prospective evaluation of the variables of 
interest and the scarcity of preliminary data to sup-
port the expected connections between biological 
and psychological characteristics of patients with 
MS.
AbStrACt
Introduction Multiple sclerosis (MS), the most common 
neurological disease causing disability in young adults, 
is widely recognised as a major stress factor. Studies 
have shown that the first years after the diagnosis are 
distressing in terms of adjustment to the disease and that 
MS negatively affects patients’ psychological well-being, 
quality of life (QoL) and social functioning. However, the 
links between disease-specific variables at diagnosis, 
resilience and psychological adjustment of patients with 
MS remain largely unexplored, especially in adolescents 
and young adults. This observational study aims to fill 
the gap of knowledge on biopsychosocial characteristics 
and resilience of young adults with MS to evaluate the 
relationship among these variables and to develop a 
biopsychosocial model of resilience.
Methods and analysis Biological and clinical 
characteristics of young adults newly diagnosed with 
MS will be investigated by collecting clinical information, 
performing neurological examinations, MRI and 
analysing cerebrospinal fluid and blood biomarkers 
(eg, measures of inflammation), body composition, 
gut microbiota and movement/perceptual markers. 
Psychosocial characteristics (eg, psychological distress, 
coping strategies), QoL, psychological well-being and 
resilience will be assessed by self-report questionnaires. 
Comparative statistics (ie, analysis of variance or unpaired 
samples t-test, correlation and regression analyses) 
will be applied to evaluate the relationship among 
biological, psychological and social factors. The results 
are expected to allow a comprehensive understanding 
of the determinants of resilience in young patients with 
MS and to inform resilience interventions, tailored to 
young patients’ specific needs, aiming to reduce the risk 
of maladaptive reactions to the disease and to improve 
psychological well-being and QoL.
Ethics and dissemination The study has been approved 
by the Verona University Hospital Ethics Committee 
(approval number: 2029CESC). The findings will be 
disseminated through scientific publications in peer-
reviewed journals, conference presentations, social media 
and specific websites.
trial registration number  ClinicalTrials. gov 
(NCT03825055).
IntroduCtIon
Multiple sclerosis (MS) is a chronic inflam-
matory disorder of the central nervous system 
pathologically characterised by the presence 
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of scattered areas of demyelination and axonal loss in the 
brain and spinal cord.1 Depending on the location and 
the accrual rate of such lesions, patients with MS experi-
ence episodes of diverse neurological symptoms, which 
are typically reversible in the early phase of the disease but 
tend to be replaced by a relentless progression of disability 
in more advanced stages.2 Being diagnosed with MS 
represents a major life event influencing individual func-
tioning and emotional well-being. For many patients, the 
first years after the diagnosis are particularly distressing in 
terms of adjustment to the disease, may negatively affect 
quality of life (QoL) and social functioning and may lead 
to psychological symptoms, such as distress, anxiety and 
depression.3–6 However, the findings regarding psycho-
pathology among adolescents and young adults with MS 
are ambiguous with two studies reporting similar levels of 
depression and anxiety between young patients and their 
healthy peers.7 8
Since MS is usually diagnosed in young adults (20–40 
years old) and increasingly in adolescents,9 10 it is 
important to consider that the personal development, 
which is crucial for young adults, may be affected and 
overshadowed by the diagnosis. Various areas of life, such 
as education, work, relationships and social participation, 
need to be adjusted to gain a new sense of coherence that 
necessarily has to include MS.7 11–13 Studies examining 
patients’ adjustments to MS demonstrated a wide range 
of possible reactions to the diagnosis and different levels 
of resilience. Indeed, evidence indicates that higher 
levels of resilience are related to lower psychopathology 
in adults newly diagnosed with MS.14 Considering the 
association between social support and mental health 
outcomes, a recent longitudinal study15 highlighted the 
mediating role of resilience in this relationship in patients 
with MS. However, the amount of received social support 
may depend on the functional limitations associated with 
MS, which may reduce participation in social life.16 17 
As Southwick et al18 stated, ‘determinants of resilience 
include a host of biological, psychological, social, and 
cultural factors that interact with one another to deter-
mine how one responds to stressful experiences’.
Personality traits have been studied as individual factors 
that can account for differences in health, well-being 
and overall QoL in MS. While some authors did not find 
different personality traits between patients with MS and 
healthy subjects, others described ‘Type D personality’, 
defined by high neuroticism, low extraversion, sometimes 
low conscientiousness, and, to a lesser extent, low agree-
ableness, in this category of patients.19–22 In a sample of 
119 adults with MS, trait mindfulness was linked to adap-
tive coping styles and increased resilience coping skills 
and higher resilience.23
Furthermore, literature has highlighted the important 
role of coping strategies in the life of patients with MS. 
A systematic review by Keramat Kar et al24 demonstrated 
that patients with MS, especially in the beginning, apply 
mainly emotional and avoidance coping strategies and 
tend to use, compared with healthy subjects, fewer active 
coping strategies. Even if coping strategies of patients 
with MS have been widely investigated, also in relation to 
psychological constructs, such as personality traits, cogni-
tive impairment and QoL,25 the impact of disease-related 
variables on the coping strategies of patients with MS and, 
in particular, on resilience mechanisms, remains largely 
underexamined. Only one systematic review26 showed 
a consistent association between coping strategies of 
patients diagnosed with life-threatening diseases, such 
as cancer, HIV/AIDS or MS and post-traumatic growth, 
which might be considered a dimension of resilience.27
Illness perception, defined as the pattern of cogni-
tive representations created by patients facing a new 
health threat,28 is considered another factor potentially 
influencing the adjustment to MS.29 30 These beliefs can 
influence coping behaviour, since negative illness percep-
tions are related to worse adjustment outcomes, slower 
recovery and increased future disability.28 For this reason, 
illness perception may influence the ability to be resilient 
facing the new MS diagnosis.
There is solid evidence that stressful life events are a 
triggering factor for MS relapses.31 32 While some earlier 
studies have also suggested an association between 
distress and the onset of MS,33 34 a recent article could not 
confirm this finding.21
Further, Benedict and colleagues19 conducted a study 
on 120 subjects with MS of any duration to assess the asso-
ciation between clinical and psychological factors and 
QoL. The findings indicated that self-reported health-re-
lated QoL was most strongly predicted by measures of 
depression, whereas employment status was primarily 
predicted by measures of cognitive function.
Also, sociodemographic factors, such as gender, age, 
education and occupational status, need to be considered 
when studying differences in adapting to MS and resil-
ience, as done in a recent review of coping with MS.24
None of the validated diagnostic and prognostic tools 
that are used in MS clinical practice (eg, type of clinical 
onset, brain and spinal cord MRI characteristics, IgG oligo-
clonal bands in the cerebrospinal fluid (CSF) and evoked 
potentials) have been specifically explored as possible 
modifiers of patients’ psychological characteristics or vice 
versa. However, it could be hypothesised that clinical and 
paraclinical features of MS directly or indirectly influ-
ence patient’s resilience strategies, by interfering with 
psychological adjustment or other mechanisms still to be 
investigated in the MS population.35 In addition, inves-
tigational biomarkers —including neurofilament light 
chain and cytokines in CSF/serum,36 37 microRNA expres-
sion in cells and tissues,38 39 oxidative stress markers in 
body fluids,40 41 gut microbiota composition,42 43 body 
composition44 45 and neurophysiological markers of 
motor–perception interactions46 47—are linked to diverse 
pathophysiological processes of MS, which could have 
direct or indirect connections to psychological factors, 
coping strategies, well-being and ultimately QoL.
A comprehensive understanding of the concept of resil-
ience in the MS field and of related factors, which may 
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Figure 1 Overview of the BPS-ARMS work packages. BPS-
ARMS, biopsychosocial characteristics and resilience of 
young adults with MS.
enhance or reduce resilience, are essential for improving 
patients’ well-being. The role of disability-specific, biolog-
ical, psychological and social factors should be explored 
adopting the well-established biopsychosocial model of 
Engel.48 Recently, Black and Dorstyn16 tested a biopsycho-
social model of resilience in 196 adults with MS. While 
positive affect and self-efficacy showed a direct effect 
on resilience, fatigue severity, physical dependence and 
social support had an indirect effect. However, the authors 
acknowledged that more than half of the variance could 
not be explained by the identified variables and therefore 
suggested to explore in future studies other key elements 
of resilience from a biopsychosocial perspective.
There is only scant research about resilience in patients 
with MS and its influencing factors, particularly in adoles-
cents and young adults. Up to now, to our knowledge, 
only one Italian study7 assessed resilience in adolescents 
and young adults newly diagnosed with MS. Moreover, 
rarely16 have been biological, psychological and social 
factors potentially associated with resilience explored in 
a holistic biopsychosocial model.
Thus, investigating resilience in this population is inno-
vative and extremely relevant for the following reasons: 
(1) youth is a critical period for the individual’s future 
development and well-being; (2) MS is the most common 
neurological disease causing disability in young people49 
and increasingly recognised in adolescents; (3) early 
interventions, focusing on young patients’ resilience, 
are crucially needed to prevent a worsening of potential 
psychological problems later on in life and to improve 
psychological well-being and QoL.
objECtIvES
Drawing on the above outlined literature, the aims of the 
biopsychosocial characteristics and resilience of young 
adults with MS (BPS-ARMS) are threefold:
Research objective 1: To assess the biological, psycho-
logical and social characteristics of a sample of young 
adults newly diagnosed with MS.
Research objective 2: To explore the resilience strat-
egies and QoL in a sample of young adults newly diag-
nosed with MS.
Research objective 3: To investigate the association 
between biopsychosocial characteristics and resilience to 
develop a biopsychosocial model of resilience in young 
adults newly diagnosed with MS.
MEthodS
Study design
The BPS-ARMS project has an observational design. It will 
last for 3 years, following two main consequential phases 
(start date: 26 February 2019, planned end date: 26 August 
2021). In the first phase, biopsychosocial factors will be 
collected and resilience strategies and QoL assessed. In 
the second one, the relationship between biopsychosocial 
factors and resilience will be explored and consequently a 
biopsychosocial model of resilience in young adults newly 
diagnosed with MS will be developed. Eleven specific 
work packages (WP) will be accomplished during these 
two phases (figure 1).
For each WP, different actions will be performed 
according to the flowchart (figure 2). WP1 actions include 
recruitment, coordination and dissemination of the 
results. WP2 aims to achieve an effective, constant collab-
oration between researchers, patients and healthcare 
providers (participatory design). WP3 is dedicated to the 
screening phase for the eligibility of patients and collec-
tion of clinical and MRI characteristics of young patients 
and analysis of protein biomarkers and 24OH-Choles-
terol. WP4 aims to collect the psychosocial characteristics 
of young patients. WP6, 7, 8, 9 and 10 aim to collect all 
the biological variables not included in WP3.
Research actions of WP3 and WP6–10 are summarised 
in table 1. WP4 procedures are reported in table 2. Explo-
ration of resilience and QoL will be performed in WP5 
and, considering the results of the previous WPs, WP11 
procedures will allow developing the biopsychosocial 
model of resilience.
Sample and setting
The BPS-ARMS project will be implemented in the 
Multiple Sclerosis Regional Center of the Azienda 
Ospedaliera Universitaria Integrata of Verona—Borgo 
Roma Hospital (Veneto Region, Italy—Hub for Verona 
Province).
Patients will be enrolled according to the following inclu-
sion criteria: age range 18–40 years; MS diagnosis in the 
2 years prior to study inclusion, according to the revised 
McDonald Criteria50; MRI of the brain in the 6 months 
prior to or within 1 month after screening visit, according 
to the protocol described below; Italian speakers.
 o
n




pen: first published as 10.1136/bmjopen-2019-030469 on 2 August 2019. Downloaded from 
4 Gajofatto A, et al. BMJ Open 2019;9:e030469. doi:10.1136/bmjopen-2019-030469
Open access 
Figure 2 Flowchart of data collection according to 
each WP. COPE, Coping Orientation to the Problems 
Experienced; CSF, cerebrospinal fluid; DXA, dual-energy 
X-ray absorptiometry; EDSS, Expanded Disability Status 
Scale; EEG, electroencephalography; miRNA, microRNA; 
NFL, neurofilament light chain; TMS, transcranial magnetic 
stimulation; WP, work package.
Table 1 Summary of the clinical and biological variables collected in WPs 3,6,7,8,9,10
Work 
package Description
WP3 Recruitment and screening phase; collection of clinical, MRI and CSF data of patients; analysis of NFL in serum/CSF by Simoa, 
Quanterix; analysis of inflammatory cytokine panel in serum/CSF by Bioplex, BioRad37; analysis of 24OH-Cholesterol esterification 
level in serum61
WP6 Analysis of microRNA levels in exosomes from serum samples. Candidate miRNAs to be analysed (miR-15b-5p, miR-374a-5p 
miR-342–3 p, miR-30b-5p, miR-223–3 p, miR-433–3 p, miR-432–5 p, miR-23a-3p, miR-485–3 p and let-7i) have been selected from 
previous studies indicating them as potential biomarkers for MS.38 39
WP7 Oxidative stress markers analysis. The concentration of glutathione and glutathione disulphide (GSH/GSSG), of nitrite/nitrate 
(NO2
−/NO3
−) as well as levels of lipid peroxidation and of oxidative post-translation modification of proteins will be evaluated in 
plasma. The activation of STAT1 signalling (phosphoTyr701-STAT1/STAT1 ratio and levels of S-glutathionylated STAT1) will be 
analysed in PBMC.40 62
WP8 Movement and perceptual markers analysis.46 47Upper extremities motor evoked potentials obtained by transcranial magnetic 
stimulation in two tasks (ie, rest and motor imagery)
WP9 Body composition analysis.44 45Bone mineral content, fat-free soft tissue mass, fat mass and percentage of fat mass will be 
measured by dual-energy X-ray absorptiometry
WP10 Gut microbiota composition.42 43A faecal sample will be collected at enrollment and analysed to assess microbiome composition 
using the percentage of bacterial subgroups at the genus level and protein concentration resulting from metaproteomics 
experiments.
CSF, cerebrospinal fluid; MS, multiple sclerosis; NFL, neurofilament light chain; PBMC, peripheral blood mononuclear cell; WP, work package.
We will exclude patients with: clinically relevant 
cognitive deficits as evaluated by the treating neurolo-
gist; treatment with any disease-modifying therapy for 
MS at inclusion and by completion of study procedures 
(maximum 2 months from consent); steroids administra-
tion up to 30 days prior to inclusion is allowed.
The effective sample size, required to allow the regres-
sion models to be reliably estimated, is 150–180 patients. 
On the basis of the setting catchment area (ie, 1800 
patients with MS annually for Verona province), we esti-
mate that the required numerosity of eligible patients will 
be reached in a time period of 30 months.
recruitment procedures
Eligible patients will be consecutively enrolled by the 
neurologists and residents working at the MS Center of 
Borgo Roma Hospital, Verona. During the first visit at the 
MS Center, the neurologists/residents will explain the 
study to eligible patients, and the consent form will be 
signed. During this visit, sociodemographic and clinical 
information will be collected, according to routine clin-
ical practice. Within 1 month from consent, patients will 
start a screening phase, which is part of the typical diag-
nostic work-up of patients with suspected MS (WP3). After 
screening completion, fulfilment of inclusion criteria and 
absence of exclusion criteria, patients will be enrolled or 
excluded from the study accordingly. Within 1 month 
from screening completion, patients included in the 
study will undergo a blood draw from a peripheral vein 
at the MS Center, and a faecal sample will be collected 
(WP 3, 6, 7 and 10). During the same visit, a psycholog-
ical battery of tests will be performed (questionnaires for 
both WP4 and WP5). Within 1 month from screening 
completion, patients can decide to be involved in addi-
tional study procedures, regarding the analysis of move-
ment and perceptual markers as well as body composition 
as measured by dual-energy X-ray absorptiometry (WP8 
and WP9) at the dedicated laboratories of the Univer-
sity of Verona. All the aforementioned procedures will 
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Table 2 Summary of the psychological variables and self-report questionnaires (WP4)
Measure Questionnaire Description of the questionnaires and variables
Symptoms of psychopathology SCL-90-R63 SCL-90-R is a 90-item questionnaire, designed to evaluate, 
on a 5-point Likert scale. A broad range of psychological 
problems and symptoms of psychopathology. The primary 
assessed dimensions are somatisation, obsessive–
compulsive, interpersonal sensitivity, depression, anxiety, 
hostility, phobic anxiety, paranoid ideation and psychoticism.
Mindfulness traits The Italian short form of FFMQ-SF64 
65
The FFMQ-SF with 24 items is used to assess major 
aspects of mindfulness skills: observing, describing, acting 
with awareness, non-judging and non-reactivity. Items are 
measured on a 5-point Likert scale.
Coping strategies The Brief COPE66–68 The Brief COPE includes 28 items, organised in 14 subscales, 
each composed of 2 items. Each item is evaluated on a 
4-point scale from 1 to 4.
Illness perception The Brief IPQ29 69–71 The Brief IPQ-R is a 9-item instrument developed to provide 
a quantitative measurement of the components of illness 
representations, evaluated on a 5-point Likert scale.
Psychosocial functioning and stressful life 
events
PSI72 73 The PSI is a scale made of 55 items providing a 
comprehensive assessment of stress, well-being, distress 
and illness behaviour.
Social support The Italian version of MSPSS74 75 The MSPSS, a 12-item measure of social support, measures 
on a 6-point Likert scale the level of perceived social support 
of various sources (eg, family, friends and significant others).
COPE, Coping Orientation to the Problems Experienced; FFMQ-SF, Five Facet Mindfulness Questionnaire Short Form; IPQ, Illness Perception 
Questionnaire; MSPSS, Multidimensional Scale of Perceived Social Support; PSI, Psychosocial Index; SCL-90-R, Symptoms Checklist 90 items 
Revised.
be completed within 2 months from informed consent 
to guarantee timely access to the more appropriated 
MS treatment for each patient as discussed between the 
treating neurologist and the patient according to clinical 
practice. Study procedures will not influence treatment 
decisions.
variables and procedures
The primary endpoint of the study is the resilience of 
patients with MS, assessed using the Connor-Davison 
Resilience Scale (CD-RISC).51 This instrument is specif-
ically designed to examine resilience features in adoles-
cents and adults. The CD-RISC is composed of 25 items 
and evaluated on a 5-point Likert scale (ranging from 0 
‘not true at all’ to 4 ‘true nearly all of the time’), with 
higher scores reflecting higher levels of resilience. This 
instrument has been selected because of its good psycho-
metric properties.51 Further, it showed the highest quality 
in a methodological review52 evaluating 15 resilience ques-
tionnaires. The psychometric properties of the Italian 
version of the 25-item CD-RISC will be described by using 
item response theory analysis on our sample of patients 
with MS. To validate this scale in the Italian language, 
a confirmatory factor analysis (CFA) will be performed. 
Furthermore, this questionnaire has already been used 
with patients with MS15 16 23 53 and translated into Italian.
The secondary endpoint is QoL, assessed using the Italian 
version of the Multiple Sclerosis Quality of Life-54 (MSQoL-
54).54 The MSQOL-54 is a multidimensional health-related 
QoL measure that combines both generic and MS-specific 
items, such as fatigue and cognitive function.54–56 The 
instrument generates 12 scores (ie, physical function, role 
limitations—physical, role limitations—emotional, pain, 
emotional well-being, energy, health perceptions, social 
function, cognitive function, health distress, overall QoL 
and sexual function) along with two summary scores (ie, 
physical health and mental health) derived from a weighted 
combination of scale scores. There are also two single-item 
measures: satisfaction with sexual function and change in 
health. The Italian version of MSQOL-54 is easy to admin-
ister and well accepted by patients.
All variables collected in the WPs 3, 4 and 6–10 (eg, clin-
ical, psychosocial, MRI and laboratory data) are used to 
describe the sample and considered as potential predic-
tors of resilience through Exploratory Factor Analysis 
(EFA).
The following sociodemographic variables will be 
collected at the recruitment for each patient through a case 
report form: age, gender, ethnicity, education level and 
occupational status.
Table 1 recaps the clinical and biological variables for 
all WPs, with the exception of WP4, for which table 2 
describes measures and the questionnaires used to collect 
the psychological measures. For the variables collected in 
WPs 3 and 6–10, preliminary measurements, obtained 
on biological samples of healthy subjects in the labora-
tories of the research team, will be used as the qualita-
tive reference. This will allow setting up the methods for 
biomarkers analysis for each WP.
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Patient and public involvement statement. Participatory 
design: research partnership with patients and associations
Patients and the public were first involved in the conclu-
sive phase of protocol preparation during a meeting with 
Verona representatives of the Italian Multiple Sclerosis 
Association (AISM) and during a public event organised 
by the University of Verona in September 2018. Psycho-
logical variables and outcome measures were developed 
based on the response to a preliminary survey that was 
conducted in a sample of patients with MS attending the 
Verona MS centre in 2017.
The Verona section of AISM will be involved in the 
recruitment process through disseminating information 
to patients and caregivers regarding the study. A patients 
advisory board (PAB) composed by young patients with 
MS and representatives of AISM will be established. 
The recruitment will be performed at the beginning of 
the project in the clinical centres and MS associations 
of patients and relatives. The PAB will collaborate and 
supervise all the research phases (including the discus-
sion, interpretation and dissemination of results) through 
regular meetings and consultations.
The participatory design of the study (WP2) will increase 
the ecological validity of our results and improve trust and 
collaboration among the MS stakeholders as a potential 
starting point for future research and care planning.
Planned analysis
An integrated database will be created and checked for 
completeness across all the collected biopsychosocial vari-
ables. It will be possible to merge the databases (ie, of WP3, 
WP4 and so on) using the unique study subject identifier. 
The statistical power analysis used to identify the sample 
size is based on the number of subjects per variable (SPV) 
approach.57 58 The literature indicates 10 as the minimum 
value of SPV. In the present study, we have set SPV at 15, 
given that we analyse one relevant variable (ie, indicator) 
for each WP (ie, WP3–WP10) and five clinical and socio-
demographic characteristics (sex, age, education level, 
Expanded Disability Status Scale score and the number of 
T2 lesions on brain MRI). These characteristics will be anal-
ysed a priori in the regression models due to the relevance 
for the resilience of patients with MS.
Since the relationship between resilience and biolog-
ical variables has been scarcely investigated in the litera-
ture, the handling of missing data could be problematic, 
particularly in case of missing not at random.59 For this 
reason, only the variables with an amount of missing data 
<10% will be included in the analysis so that the results 
can be considered robust and accurate.
To identify the indicator for each WP to be included 
in the final biopsychosocial model of resilience, an EFA 
will be performed using each WP variable measured as 
factors. The first factor (ie, the one explaining most of the 
variability) will be selected as the indicator for the specific 
WP. Applying generalised linear regression models, we 
will preliminarily explore (1) the relationship among 
the different WP indicators and (2) the relationship 
between each WP indicator and resilience. The selected 
WP indicators will be jointly explored using multivariable 
models to quantify the main relationships. The results of 
the regression analyses will lead to the development of 
a biopsychosocial model of resilience. Given the paucity 
of evidence in this field, we will proceed gradually in the 
design of the model, applying different statistical tech-
niques according to the critical issues that will potentially 
emerge from the preliminary descriptive analysis. If the 
main assumptions of Structural Equation Models (ie, the 
sample size of groups, the normality of frequency distri-
bution of the variables of interest, the absence of outliers) 
will be satisfied, it will be possible to perform also CFAs. 
This method will allow the goodness of fit of our biopsy-
chosocial model to be assessed.
The same procedure will be applied at the secondary 
endpoint of the study to build a biopsychosocial model of 
QoL. Statistical analyses will be carried out using Stata V.15.60
EthICS And dISSEMInAtIon
Ethics and safety
The project will be conducted according to the approved 
protocol. All data collected during the project will be 
handled fairly, and the databases will remain strictly confi-
dential, anonymised, password protected and stored in 
locked and secured facilities at the Department of Neuro-
science, Biomedicine and Movement Sciences, University 
of Verona.
In detail, patients who sign the informed consent 
form and comply with all of the inclusion criteria will be 
assigned a unique study subject identifier (ie, a pseud-
onym or alias). Only the authorised study personnel will 
have access to the matching between the subject identi-
fier and patient identity. The study subject identifier will 
remain the same during the whole study and will allow 
the proper handling of the patients’ data and samples 
without using sensitive personal identifiers. Data will be 
collected in a dedicated case report form and entered 
into an electronic database for analysis.
The collected biological samples will be stored at the 
Neuropathology Laboratory of the University Hospital 
of Verona for 10 years and may be used for additional 
research conducted at the University of Verona and 
related to the present study. Following the completion of 
the study, leftover samples sent to the laboratories of the 
“Centro Interuniversitario di Ricerca sui Peptidi Bioat-
tivi” (CIRPEB, Research Centre on Bioactive Peptides), 
Napoli (see WP3) will be destroyed after analysis.
dissemination plan
A dissemination plan will be established in the first 
phase of the project in agreement with all the involved 
researchers during a dedicated meeting. The dissemi-
nation target will be different stakeholders (eg, other 
researchers, patients, MS representatives and associa-
tions, healthcare professionals, the general public). Each 
dissemination product will be tailored to these different 
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target groups in terms of objectives, methods, timeline 
and language (eg, youth-friendly language and format). 
Facebook and specific websites will be used to dissemi-
nate the materials of the project. The use of these social 
media channels will allow a broader dissemination of the 
project results. The scientific community will be reached 
through scientific publications in national and interna-
tional preferably open access journals and presentations 
at national and international scientific conferences. Items 
for dissemination in any format including publications 
will not contain any information that could lead to the 
identification of the patients.
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